Want to see HK:2393 full AI Analyst Report?
Top Page
Yestar Healthcare Holdings Co Ltd
(2393)
Select Model
Select Model
Rating:55Neutral
Price Target:
HK$0.07
▲(16.67% Upside)
Action:Reiterated
Date:09/27/26
The score is driven primarily by mixed financial performance: strong recent cash generation and an improved balance sheet are positives, but they are tempered by a sharp revenue decline and unstable profitability (including a net loss). Technicals are supportive in the short term (price above key shorter moving averages and positive MACD) but look stretched (overbought signals) and still weak versus the 200-day trend. Valuation is constrained by loss-making results (negative P/E) and no available dividend yield.
Positive Factors
Cash Generation
Strong 2025 operating and free cash flow indicates that the company converted its healthcare services into meaningful cash despite reporting a net loss. If maintained, this supports clinic investment, working-capital needs, and financial resilience without relying as heavily on external funding.
Negative Factors
Revenue Contraction
The sharp decline in annual revenue indicates weakened demand or service volume and directly reduces the scale available to absorb clinic and operating costs. Continued top-line pressure could limit reinvestment, weaken utilization, and make a sustained recovery in earnings more difficult.
Read all positive and negative factors
Positive Factors
Negative Factors
Cash Generation
Strong 2025 operating and free cash flow indicates that the company converted its healthcare services into meaningful cash despite reporting a net loss. If maintained, this supports clinic investment, working-capital needs, and financial resilience without relying as heavily on external funding.
Read all positive factors
Yestar Healthcare Holdings Co Ltd (2393) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$149.10M
Dividend Yield2.02%
Average Volume (3M)127.16K
Price to Earnings (P/E)―
Beta (1Y)0.61
Revenue Growth-28.07%
EPS Growth47.54%
CountryHK
Employees400
SectorHealthcare
Sector Strength45
IndustryMedical - Distribution
Share Statistics
EPS (TTM)-0.04
Shares Outstanding2,331,590,000
10 Day Avg. Volume149,500
30 Day Avg. Volume127,163
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.56
Price to Sales (P/S)0.14
P/FCF Ratio0.73
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Yestar Healthcare Holdings Co Ltd Business Overview & Revenue Model
Company Description
Yestar Healthcare Holdings Company Limited, an investment holding company, manufactures, distributes, and sells medical imaging products in Mainland China. The company operates in two segments, Imaging Printing Products, and Medical Products and E...
How the Company Makes Money
Yestar Healthcare primarily generates revenue by charging customers for services delivered at its medical facilities. Its revenue model is based on service fees paid by patients for (i) medical aesthetic procedures and treatments (such as non-surg...
Yestar Healthcare Holdings Co Ltd Financial Statement Overview
Summary
Income Statement
41
Neutral
Balance Sheet
58
Neutral
Cash Flow
72
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.35B | 1.49B | 2.41B | 2.91B | 2.80B | 4.93B |
| Gross Profit | 278.09M | 266.86M | 399.20M | 512.78M | 397.55M | 848.70M |
| EBITDA | 50.24M | 50.38M | -40.14M | 376.81M | 19.13M | 417.27M |
| Net Income | -83.96M | -75.03M | 921.61M | -13.89M | -992.23M | 3.33M |
Balance Sheet | ||||||
| Total Assets | 1.13B | 1.19B | 1.43B | 3.43B | 3.37B | 4.56B |
| Cash, Cash Equivalents and Short-Term Investments | 194.45M | 256.26M | 151.78M | 251.56M | 418.15M | 751.77M |
| Total Debt | 202.47M | 211.05M | 316.90M | 1.63B | 1.90B | 1.79B |
| Total Liabilities | 712.76M | 780.27M | 921.84M | 3.82B | 3.71B | 3.73B |
| Stockholders Equity | 379.55M | 378.26M | 461.60M | -457.50M | -408.87M | 755.23M |
Cash Flow | ||||||
| Free Cash Flow | 85.09M | 289.40M | -26.45M | 294.22M | -115.58M | 665.55M |
| Operating Cash Flow | 146.19M | 311.31M | 12.72M | 387.67M | -91.73M | 715.22M |
| Investing Cash Flow | -68.07M | -16.97M | 380.42M | -89.82M | -18.72M | -47.67M |
| Financing Cash Flow | -129.21M | -153.52M | -502.63M | -234.37M | -180.86M | -654.20M |
Yestar Healthcare Holdings Co Ltd Technical Analysis
Negative
0.06
Price Trends
0.06
Negative
0.06
Negative
0.08
Negative
Market Momentum
>-0.01
Positive
37.61
Neutral
27.08
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2393, the sentiment is Negative. The current price of 0.06 is below the 20-day moving average (MA) of 0.07, below the 50-day MA of 0.06, and below the 200-day MA of 0.08, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 37.61 is Neutral, neither overbought nor oversold. The STOCH value of 27.08 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2393.
Yestar Healthcare Holdings Co Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | HK$468.67M | 4.77 | 13.95% | 6.48% | 10.95% | 9.26% | |
64 Neutral | HK$840.68M | 9.38 | 2.40% | 5.29% | 4.57% | -24.35% | |
57 Neutral | HK$1.75B | -29.62 | -3.50% | ― | 9.36% | -153.54% | |
55 Neutral | HK$149.10M | -1.60 | -22.16% | 2.02% | -28.07% | 47.54% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | HK$2.65B | -15.75 | -7.65% | ― | 21.23% | 36.89% | |
44 Neutral | HK$432.19M | -0.78 | -28.24% | ― | -38.15% | 25.70% |
* Healthcare Sector Average
HK:2393
Yestar Healthcare Holdings Co Ltd
0.06
-0.07
-50.77%
HK:9996
Peijia Medical Ltd.
3.92
-2.08
-34.67%
HK:6669
Acotec Scientific Holdings Limited
5.58
-6.52
-53.93%
HK:1612
Vincent Medical Holdings Limited
0.71
-0.12
-14.25%
HK:1696
Sisram Medical Ltd.
1.80
-2.70
-60.09%
HK:2500
Venus Medtech (Hangzhou), Inc. Class H
0.98
-1.76
-64.23%
Yestar Healthcare Holdings Co Ltd Corporate Events
Yestar Healthcare Swings to Small Interim Loss Despite Higher Gross Profit
Aug 28, 2026
Yestar Healthcare reported unaudited interim revenue of RMB661.6 million for the six months ended 30 June 2026, down from RMB802.6 million a year earlier, while gross profit improved to RMB144.8 million from RMB133.7 million as cost of sales decli...
Yestar Healthcare Flags Interim Loss as China Bulk-Buy Schemes Squeeze Medical Product Revenue
Aug 17, 2026
Yestar Healthcare warned that it expects to report an unaudited consolidated net loss of at least RMB0.45 million for the six months ended 30 June 2026, a sharp reversal from an unaudited net profit of about RMB11.1 million a year earlier. The com...
Yestar Healthcare Sets Late-August Board Meeting to Review Interim Results and Potential Dividend
Aug 17, 2026
Yestar Healthcare Holdings has scheduled a board meeting for 28 August 2026 to review and approve its unaudited consolidated interim results for the six months ended 30 June 2026. The board will also consider declaring an interim dividend, signali...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.